Stock Research for NLNK

NLNK

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

NLNK Stock Chart & Research Data

The NLNK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the NLNK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


NLNK Due diligence Resources & Stock Charts

The NLNK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View NLNK Detailed Price Forecast - CNN Money CNN View NLNK Detailed Summary - Google Finance
Yahoo View NLNK Detailed Summary - Yahoo! Finance Zacks View NLNK Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View NLNK Trends & Analysis - Trade-Ideas Barrons View NLNK Major Holders - Barrons
NASDAQ View NLNK Call Transcripts - NASDAQ Seeking View NLNK Breaking News & Analysis - Seeking Alpha
Spotlight View NLNK Annual Report - CompanySpotlight.com OTC Report View NLNK OTC Short Report - OTCShortReport.com
TradeKing View NLNK Fundamentals - TradeKing Charts View NLNK SEC Filings - Bar Chart
WSJ View Historical Prices for NLNK - The WSJ Morningstar View Performance/Total Return for NLNK - Morningstar
MarketWatch View the Analyst Estimates for NLNK - MarketWatch CNBC View the Earnings History for NLNK - CNBC
StockMarketWatch View the NLNK Earnings - StockMarketWatch MacroAxis View NLNK Buy or Sell Recommendations - MacroAxis
Bullish View the NLNK Bullish Patterns - American Bulls Short Pains View NLNK Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View NLNK Stock Mentions - StockTwits PennyStocks View NLNK Stock Mentions - PennyStockTweets
Twitter View NLNK Stock Mentions - Twitter Invest Hub View NLNK Investment Forum News - Investor Hub
Yahoo View NLNK Stock Mentions - Yahoo! Message Board Seeking Alpha View NLNK Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for NLNK - SECform4.com Insider Cow View Insider Transactions for NLNK - Insider Cow
CNBC View NLNK Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for NLNK - OTC Markets
Yahoo View Insider Transactions for NLNK - Yahoo! Finance NASDAQ View Institutional Holdings for NLNK - NASDAQ


Stock Charts

FinViz View NLNK Stock Insight & Charts - FinViz.com StockCharts View NLNK Investment Charts - StockCharts.com
BarChart View NLNK Stock Overview & Charts - BarChart Trading View View NLNK User Generated Charts - Trading View




Latest Financial News for NLNK


Edited Transcript of NLNK earnings conference call or presentation 1-Nov-18 8:30pm GMT
Posted on Friday November 16, 2018

Q3 2018 NewLink Genetics Corp Earnings Call


NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
Posted on Thursday November 15, 2018

NewLink Genetics Corporation (NLNK) reported today that Merck has begun the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated).  This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by Merck in July 2016 and is anticipated to be completed in 2019.


NewLink Genetics Presents Phase 1 Data Supporting Significantly Higher Exposure with Indoximod Prodrug, NLG802, and Biomarker Data from Two Phase 2 Trials Illustrating Indoximod’s Impact on the Tumor Microenvironment at SITC 2018
Posted on Friday November 09, 2018

AMES, Iowa, Nov. 09, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that data from three separate trials are being presented at the Society for Immunotherapy of.


NewLink Genetics Announces Publication of Abstracts for Presentation at the Society for Immunotherapy for Cancer (SITC) Conference
Posted on Tuesday November 06, 2018

AMES, Iowa, Nov. 06, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the following abstracts have been published and are now available on the Society.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.